A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation

Biology of Blood and Marrow Transplantation

Volumn 4, Issue 1, 1998, Pages 13-19

  Boeckh, Michael ^a   Zaia, John A ^b   Jung, Donald ^c   Skettino, Sandra ^c   Chauncey, Thomas R ^d   Bowden, Raleigh A ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c Roche Global Development   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acute graft vs. host disease; Adverse events; Cytomegalovirus

Indexed keywords

GANCICLOVIR;

ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; BONE MARROW TRANSPLANTATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION;

EID: 0031610546     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(98)90005-2     Document Type: Article

References (25)

1. Goodrich JM, Boeckh M, Bowden R: Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 19:287, 1994.
2. Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, Buhles WC, DeArmond B, Meyers JD: Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 325:1601, 1991.
3. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD: Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118:173, 1993.
4. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA, City of Hope-Stanford-Syntex CMV Study Group: A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 324:1005, 1991.
5. Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC, Champlin RE: Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. results of a placebo-controlled double-blind trial. Ann Intern Med 118:179, 1993.
6. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G, Mackes P, Hertes M, Klingebiel T, Löffler J, Wagner S, Müller CA: Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86:2815, 1995.
7. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA: Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 88:4063, 1996.
8. Spector SA, McKinley GF, Lalezari JP, Samo T, Andruczk R, Follansbee S, Sparti PD, Havlir DV, Simpson G, Buhles W, Wong R, Stempien MJ, Roche Cooperative Oral Ganciclovir Study Group: Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 334:1491, 1996.
9. Gane E, Saliba F, Valdecasas GJC, O'Grady J, Pescovitz MD, Lyman S, Robinson CA: Efficacy and safety of oral ganciclovir in the prevention of CMV disease in liver transplant recipients - results of a randomized clinical trial. Lancet 350:1729, 1998.
10. Meyers JD, Flournoy N, Thomas ED: Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 153:478, 1986.
11. Meyers JD, Ljungman P, Fisher LD: Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. J Infect Dis 162:373, 1990.
12. Atkinson K, Biggs JC, Britton K, Short R, Mrongovius R, Concannon A, Dodds A: Oral administration of cyclosporin A for recipients of allogeneic bone marrow transplants: implications of clinical gut dysfunction. Br J Haematol 56:223, 1984.
13. Vogelsgang GB, Hess AD, Ling C, Brundett RB, Colvin OM, Wingard JR, Saral R, Santos GW: Thalidomide therapy of chronic GVHD. Blood 70 (Suppl 1):315a, 1987. [abstr]
14. Anderson RD, Griffy KG, Jung D, Dorr A, Hulse JD, Smith RB: Ganciclovir absolute bioavilability and steady-state pharmacokinetics after oral administration of two 3000 mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. Clin Ther 17:425, 1995.
15. Spector SA, Busch DF, Follansbee S, Squires K, Lalezari JP, Jacobson MA, Connor JD, Jung D, Shadman A, Mastre B, Buhles W, Drew WL, AIDS Clinical Trials Group, Cytomegalovirus Cooperative Study Group: Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. J Infect Dis 171:1431, 1995.
16. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED: 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825, 1995.
17. Deeg J, Huss R: Acute graft versus host disease. In: K Atkinsons (ed) Clinical Bone Marrow Transplantation. Cambridge: Cambridge University Press, 1994.
18. Boeckh M, Gallez-Hawkins GM, Myerson D, Zaia JA, Bowden RA: Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation 64:108, 1997.
19. Boeckh M, Gleaves CA, Bindra R, Meyers JD. Comparison of MRC-5 and U373MG astrocytoma cells for detection of cytomegalovirus in shell vial centrifugation cultures. Eur J Clin Microbiol Infect Dis 10:569, 1991.
20. Gallez-Hawkins GM, Tegtmeier BR, ter Veer A, Niland JC, Forman SJ, Zaia JA: Evaluation of a quantitative plasma PCR plate assay for detecting cytomegalovirus infection in marrow transplant recipients. J Clin Microbiol 35:788, 1997.
21. Page T, Sherwood C, Connor JD, Tarnowski T: Simple reversed-phase high-performance liquid chromatography quantitation of ganciclovir in human serum and urine. J Chromatogr B Biomed Appl 675:342, 1996.
22. Salzberger B, Bowden RA, Hackman R, Davis C, Boeckh M: Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of CMV disease: risk factors and outcome. Blood 90:2502, 1997.
23. Lavelle J, Follansbee S, Trapnell CB, Buhles WC, Griffy KG, Jung D, Dorr A, Connor J: Effect of food on the relative bioavailability of oral ganciclovir. J Clin Pharmacol 36:238, 1996.
24. Fink JC, Cooper MA, Burkhart KM, McDonald GB, Zager RA; Marked enzymuria after bone marrow transplantation: a correlate of veno-occlusive disease-induced "hepatorenal syndrome." J Am Soc Nephrol 6: 1655, 1995.
25. Markham A, Faulds D: Ganciclovir: an update of its therapeutic use in cytomegalovirus infection. Drugs 48:455, 1994.